» Articles » PMID: 10466818

Antigenic Domain 1 of Human Cytomegalovirus Glycoprotein B Induces a Multitude of Different Antibodies Which, when Combined, Results in Incomplete Virus Neutralization

Overview
Journal J Gen Virol
Specialty Microbiology
Date 1999 Aug 31
PMID 10466818
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Glycoprotein B (gB, gpUL55) is the major antigen for the induction of neutralizing antibodies against human cytomegalovirus (HCMV), making it an attractive molecule for active and passive immunoprophylaxis. The region between aa 552 and 635 of HCMV gB (termed AD-1) has been identified as the immunodominant target for the humoral immune response following natural infection. AD-1 represents a complex domain which requires a minimal continuous sequence of more than 70 aa for antibody binding. Neutralizing as well as non-neutralizing antibodies can bind to AD-1 in a competitive fashion. The fine specificity of AD-1-binding monoclonal antibodies (MAbs) and affinity-purified human polyclonal antibodies was analysed by using recombinant proteins containing single amino acid substitutions spanning the entire AD-1 domain. Our results revealed that all MAbs had individual patterns of binding to the mutant proteins indicating the presence of a considerable number of distinct antibody-binding sites on AD-1. The neutralization capacity of antibodies could not be predicted from their binding pattern to AD-1 mutant proteins. Polyclonal human antibodies purified from different convalescent sera showed identical binding patterns to the mutant proteins suggesting that the combined antibody specificities present in human sera are comparable between individuals. Neutralization capacities of polyclonal human AD-1 antibodies did not exceed 50% indicating that, during natural infection, a considerable proportion of non-neutralizing antibodies are induced and thus might provide an effective mechanism to evade complete virus neutralization.

Citing Articles

A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.

Gomes A, Baraniak I, McIntosh M, Sodi I, Langstone T, Siddiqui S J Gen Virol. 2023; 104(6).

PMID: 37310000 PMC: 10661908. DOI: 10.1099/jgv.0.001860.


A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B.

Okamoto M, Kurino R, Miura R, Takada K PLoS One. 2023; 18(5):e0285672.

PMID: 37192198 PMC: 10187921. DOI: 10.1371/journal.pone.0285672.


A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.

Li L, Freed D, Liu Y, Li F, Barrett D, Xiong W NPJ Vaccines. 2021; 6(1):79.

PMID: 34078915 PMC: 8172929. DOI: 10.1038/s41541-021-00342-3.


A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Choi K, El-Hamdi N, McGregor A J Gen Virol. 2021; 102(3).

PMID: 33729125 PMC: 8148303. DOI: 10.1099/jgv.0.001579.


Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion.

Liu Y, Heim K, Che Y, Chi X, Qiu X, Han S Sci Adv. 2021; 7(10).

PMID: 33674318 PMC: 7935361. DOI: 10.1126/sciadv.abf3178.